Company intelligence / Profile preview

Andelyn Biosciences

Ownership: Private
Development stage: Commercial

Overview

Andelyn Biosciences is a commercial-stage CDMO specializing in viral vector manufacturing for gene therapies. It supports clients from preclinical development through commercialization, primarily focusing on rare diseases and genetic disorders. The company originated from Nationwide Children's Hospital and utilizes its proprietary AAV Curator® Platform for process optimization.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Viral vectorsPlasmid manufacturingAdeno-associated virus (AAV) vectors
Industry: Contract Manufacturing Organization

Partnerships

Pall CorporationCytiva

Beyond the preview

Go deeper on Andelyn Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Andelyn Biosciences.

Explore the full profile